🔗 Share this article

As America undertakes historic changes to its vaccination schedules, an unexpected name has surfaced in a surprising turn: Tracy Beth Høeg, a Danish American sports physician and public health researcher who rose to prominence by expressing skepticism about coronavirus vaccines throughout the pandemic and has focused upon alleged deaths following COVID-19 vaccination in her brief tenure at the Food and Drug Administration.

Planned Overhauls to Pediatric Immunization Schedule

Health officials were set to reveal major changes to the pediatric vaccine schedule in December, aligning the US with Denmark’s national calendar, it is understood – a substantial departure that would place the US at odds with many the world with little proof for public health gain. The planned update has been delayed until the new year.

Rather than Vinay Prasad, Tracy Beth Høeg is scheduled to speak at the event. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this year.

Consolidating Power at the Regulatory Body

The acting appointment may indicate a strengthened alliance between the drug and vaccine centers as Høeg and Dr. Prasad solidify control at the agency – and it signals a renewed priority upon reevaluating long-standing vaccines at the FDA.

The new acting director has repeatedly called for ending some pediatric shot schedules in the US in order to be more like the Danish model, a country with nationalized medicine and a number of inhabitants approximately the size of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on vaccines – usually the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Concerns Over Expertise

The appointee has no obvious background in pharmaceutical research, approval processes or administrative roles, which has been standard for previous directors of the biologics center. She has served at the FDA as a senior adviser to the commissioner and the vaccine center since spring.

“It seems she lacks to have any of the qualifications” for leading the drug-regulation department, stated a neurologist and psychiatrist. “She has not conducted a clinical trial. She lacks experience in leading a sizeable institution. She is not an expert in industry regulation.”

Past heads of CBER would “grasp legal statutes and the research of medication creation”, said Dr. Janet Woodcock. “Clearly, she lacks the sort of resume that prior appointees who led the center have had.”

The drug center has an enormous workload at the FDA, Woodcock emphasized.

“The public just focuses on the new drug program, but the generic program approves numerous generic medications. There’s a biosimilars program, non-prescription drug unit and so forth, and all of those must be supervised,” Woodcock noted. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Furthermore, a significant leadership component to the job, which supervises more than 5,000 employees. “It is a massive management job, if you do it right,” she said.

Agency Reaction and Disputed Programs

Regarding questions about Høeg’s qualifications and whether this assignment represents greater collaboration among regulatory chiefs on vaccines, a representative responded that the “concerns stem from incorrect presumptions”.

“Her resume aligns with the functions of her role,” the spokesperson said, noting the time Dr. Høeg spent counseling the agency head on “drug safety and regulatory science, including computational safety modeling and immunization monitoring”.

As acting director, Høeg assumes responsibility for the commissioner’s new expedited review system, a controversial expedited drug-approval program that reportedly troubled her preceding directors. “How are these drugs being picked for this fast-track system? Who takes the calls?” Dr. Howard questioned. “There is a lot of lack of transparency happening at the agency right now.”

In general, he stated, “the Food and Drug Administration looks to be trending towards more relaxed rules of pharmaceuticals, aside from vaccines.”

Documented History on Vaccines

Regarding vaccines, Dr. Høeg has a clearer, if concerning, past, critics observe. She published a research paper using non-validated public submissions to estimate the incidence of heart inflammation following Covid vaccination. She counseled the Florida top health official Joseph Ladapo, who reportedly have altered data to imply Covid vaccinations are pose a greater threat than they are.

Part of her “wish list” for the current federal leadership included changing guidelines for recently developed shots and halting “unnecessary” vaccines, she stated after the election on a audio program. At the agency, Høeg has according to sources suggested barring teenage boys from getting Covid vaccinations.

“She’s an all-around true believer who starts off with her preconceived notions and tailors the evidence to fit the data in a extremely misleading, untruthful fashion,” Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg joined fellow contrarians, {like|